NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.[2]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C27H33N3OS |
Molar mass | 447.64 g·mol−1 |
3D model (JSmol) |
|
|